3 articles
NVIDIA's BioNeMo platform is anchoring AI drug discovery partnerships with Eli Lilly and Thermo Fisher, cementing a scale-first infrastructure play. Novo Nordisk's 24.9% 30-day stock surge and strong Q1 2026 earnings reinforce market conviction in AI-powered pipelines. But purpose-built challengers—Natera, Owkin, Boltz Lab—are mounting a direct bid for the same enterprise R&D budgets.
Corning shares have risen 137.4% year to date, powered by an expanded long-term partnership with NVIDIA and surging demand for fiber optic components in AI data centers. The company plans three new manufacturing facilities to meet buildout requirements. Enterprise AI adoption is accelerating the need for high-capacity optical interconnects.
NVIDIA secured partnerships with Thermo Fisher and Eli Lilly for its BioNeMo platform as specialized biological AI models compete against general-purpose systems in early 2026. Multiple AI platforms from Basecamp Research, Boltz Lab, Owkin, and Edison Scientific launched simultaneously, marking a shift toward purpose-built foundation models for pharmaceutical R&D.